Subject Index

Acetylcholine metabolism, 532
Acetylcholine receptor
  antibodies to, 68, 110
  chromosomal localization of genes and, 166
  degradation of, 156
  embryonic muscle, 213
  immunocytochemical analysis of, 502
  interaction of acetylcholine with, 487
  main immunogenic region of, 172, 200
  mongoose, 133
  muscarinic, 415
  nicotinic, 126, 140, 147
  rapidly degrading, 156
  skeletal muscle nicotinic, 103, 435
  snake, 127
  synthetic peptides of, 332–334
  thymic α-3, 83
Acetylcholine receptor α138–199, 295
Acetylcholine receptor α-subunit, 201
Acetylcholine receptor ion channel
  amphiphilic ridge in, 115
  closed, open, and desensitized states in, 119
Acetylcholine receptor subunit, organization of, 121
Acetylcholine receptor turnover, 298
Acetylcholine receptor-coupled syngeneic cells, 306–309
Acetylcholine release, 368
Acetylcholinesterase, congenital end-plate, 469
Acetylcholinesterase staining, 455
Alpha-subunit Cys 192–193, 336
Alternate splicing, 79
Alu splicing, 93
β-Amyloid precursor protein, thymic stromal fraction and, 87
Anatoxin-α, 150
Anergy
  clonal B-cell, 30
  tolerance and, 8–10
Anomalous scattering X-ray experiments, 114
Anti–ω-type voltage-operated calcium channel antibodies, 375
Antiacetylcholine receptor antibody, epitope of, 175
Antiacetylcholine receptor cells in healthy control, 212
Antiacetylcholine receptor monoclonal antibody, interaction of, 172
Antiaxonal autoimmunity, thymic epithelial tumors and, 107
Antibodies, L-type calcium channels and, 358
Antibody specificity, 179
Anticholinesterases, neuromuscular transmission failure and, 402
Antigen presentation, 306–307
Antigen-presenting cells, 521
Antigenic conformation, 171
Antigen processing, 221
Antipeptide antibody, 169, 170
Antisense Alu sequence, 90
Anti–voltage-operated calcium channel antibodies, 377
Autoantibodies
  generation of, 29–31
  Lambert-Eaton myasthenic syndrome, 394, 398
  presynaptic calcium channels and, 418
Autoepitope, T-cell, 4
Autoimmune diseases, 37–41
Autoimmunity, T-cell tolerance and, 35–37
Autonomic function, congenital end-plate acetylcholinesterase deficiency and, 470
Autosensitization, 219
Azathioprine, 541, 599, 606
  relapses of patients treated with, 591

B-cell activation, 26
B cells
  human acetylcholine receptor-reactive, 340
  memory, 30
  pancreatic, 375
B lymphocytes, antibody-producing, 256–261
Beta-subunit of calcium channel complexes, 408
Benzoquinonium, 147
Binding site, novel, 152
Bovine adrenal chromaffin cells, 394
BS_3, 535
α-Bungarotoxin, 126, 213
[^{125}I]α-Bungarotoxin binding, 455

C cells, thyroid, 398, 400
Calcium antagonist drugs, 346
Calcium channels
  L-type, 394, 398
  molecular properties of, 342
  N-type, 383, 398
  P-type, 386, 405
  presynaptic, 368
  T-type, 398
  types of, 356
  voltage-gated, 422

Calcium currents, 369
  effects of Lambert-Eaton myasthenic syndrome serum and immunoglobulin G on, 418
cAMP, 345
  dibutyryl, 155
Cancer, lung, 377
Carbamates, direct action of on nicotinic acetylcholine receptor, 140–141
Carboxylates, ring of, 115
Carcinoma, small-cell lung, 377
$CD4^+$ T cell, heterogeneity of, 25
$CD4^+$ T-cell lines, 220
$CD5^+$ B cells, 258
$CD8^+$ cells, 214
Channel types, 356
Chimeric anti-CD4 monoclonal antibody, 552
Cholinergic binding site, 126
Clinical features in congenital end-plate acetylcholine receptor deficiency, 469, 510
Clinical features in congenital myasthenic syndrome, 488
Clinical features in myasthenic syndromes affecting ε-subunit of acetylcholine receptor, 496
Clinical features in short channel open time, 510
Clinical improvement, anti-CD4 monoclonal antibody and, 552
Clinical therapeutic trial of cyclosporine, 539
Clonal anergy, 308–309
Clonal deletion
  B-cell, 30
  self-tolerance and, 10–11
Clones, genomic, 165
Complement, 70, 269
Congenital end-plate acetylcholine receptor deficiency, short channel open time and, 509
Congenital end-plate acetylcholinesterase deficiency
  possible causes of, 484
  spectrum of, 469
Congenital myasthenic syndrome
  abnormal acetylcholine-acetylcholine receptor interaction and, 487
  clinical observations in, 451
  electron microscopy in, 465
  ε-subunit of acetylcholine receptor and, 496
  nicotinic AChR changes in, 435
  pathologic mechanisms in, 467
  possible causes of, 492
  presynaptic defect and, 461
Congenital myasthenic syndromes, classification of, 426
ω-Conotoxin, 347
  voltage-operated calcium channels subtype labeled by, 373
Consensus analysis, 410
Corticosteroid therapy, 539
Cs^+ flux, 145
Cyclophosphamide, 246
Cyclosporine, clinical therapeutic trial of, 539
Cytokines, production of, by peripheral blood lymphocytes of myasthenia gravis patients, 315–318

3-Deazaadenosine, 298
Degradation, acetylcholine receptor, 155
Dendrites, 352
3,4-Diaminopyridine, 452, 588
Differential recognition by T cells, 280
Dihydropyridine, 394
Diisopropylfluorophosphate, neuromuscular transmission and, 402
Disease severity, ability to predict, 179
DPB1 allele, 570
$DQ\alpha/\beta$ heterodimers, 573
DR4 subtypes, 223
Dystrophin-related protein, 249

Edrophonium test, intravenous, 428
Electromyographic studies, 428, 497
Electron microscopy, 113
  abnormal acetylcholine-acetylcholine receptor interaction and, 490
  congenital end-plate acetylcholine receptor deficiency and short channel open time and, 511
  congenital myasthenic syndrome and, 430, 465
  end-plate acetylcholinesterase deficiency and, 474
Electrophysiologic studies, *in vitro*, 472
Electrophysiologic studies in acetylcholine-acetylcholine receptor interaction, 490
End-plate, 70, 155
End-plate simplification, 266
End-plate ultrastructure, 498
Endocytosis, reducing, of acetylcholine receptors, 298
Epithelial cells, thymic, and high interleukin-6 expression, 97
Epithelial tumors, thymic, 57
  neurofilament expression by, 107
Epitope repertoire, 204, 207
Epitopes
  mapping of, in projection, 123
  T-cell, mapping of, 224, 233
  T-helper, 198

Eserine, 140
Exocytosis, Ca^{2+}-dependent, 399
Exon 3A, 78–79
Extraocular muscle, 238–253

Fas antigen, 31
FK506, 539
Fluorometric microscopy, extraocular muscle fibers and, 246
Fourier image analysis, 113
Funnel web spider toxin, 364

Genes, T-cell receptor, 33
Gram-negative pneumonia, 562

Hemocyanin, 289
Heterobifunctional antibody conjugates, 325–328
High-conductance fast-channel syndrome, 432
Hippocampal neuron, rat, 147, 149
Histochemical experiments, mongoose acetylcholine receptor in, 133
History of myasthenia gravis, 47
HLA class II antigens, 570, 581
HLA-A2–binding acetylcholine receptor peptides, 279
HLA restriction, 223, 234
Hoppe, Hermann, 56
Human muscle acetylcholine receptor-reactive T and B lymphocytes, 339–341

Imaging procedures, reliability of, 575
Immunochemical studies, 429
Immunocytochemical studies in end-plate acetylcholinesterase deficiency, 473
Immunodominant regions, 204, 209
Immunogenetics, 329–330
Immunoglobulin G, intravenous high-dose, 563
Immunoglobulin gene rearrangement, 29–30
Immunoglobulin-isotype switching, 26–27
Immunomagnetic beads, 230
Immunomagnetic particles, 288
Immunoregulation, promotion of autoimmune disease and, 12
Immunosuppressive therapy, 548
Immunosuppressive treatments, 594
Immunotherapy, 306, 577
Impulse blocking, 567
IMR32 cells, 374
Infections, hospitalized myasthenia gravis patients with, 561
Inflammation, monoclonal antibody injection and, 269
Influenza A virus matrix protein, 276
Interferon-γ gene, underexpression of, in myasthenia gravis, 102
Interleukin-2, response of peripheral blood mononuclear cells to, 323
Interleukin-2 receptor, abnormal immunoregulation involving, 283
Interleukin-6, overproduction of, 97
Interleukins, *in situ* production of, 100
Isoelectric focusing, 182, 187

K^b restricted repertoire, 16–23

Lambert-Eaton myasthenic syndrome
autoantibody specificities in, 382
calcium channels and, 356
congenital, 457
3,4-diaminopyridine in, 588
muscarinic acetylcholine receptor and, 415
small-cell lung cancer and, 418
tissue distribution of α2-δ subunit genes in, 422
Lambert-Eaton myasthenic syndrome immunoglobulin G, effect of
in BAC cells, 394
in thyroid C-cell line, 398
Leakiness, transplantation of myasthenic thymus and, 70
Lectins, effect of, on carbachol-induced $^{22}Na^+$ flux, 535

Major histocompatibility complex class II, soluble, 577
Membrane capacitance, 398
Mestinon, 604
Methyllycaconitine, 147
Microelectrode studies, *in vitro*, 462, 499, 511
Miniature end-plate potential, 452
Miniature end-plate potential amplitudes, 531
Molecular genetic studies in end-plate acetylcholinesterase deficiency, 478
Molecular structure, 274
Monoclonal antibodies, 123
agonist-site directed, 172
antiacetylcholine receptor, 285
Monoclonal antibody : acetylcholine receptor complexes, rate of dissociation of, 177
Monoclonal antibody 5.5, 135
Monoclonal antibody 35, 189
Monoclonal antibody FK1, 145, 147
Motor innervation pattern, 240

Mouse
  severe combined deficient myasthenic, 303
  severe combined immunodeficient, 66–72
  thymic cell lines in, 75–78
  transgenic, 30
Mouse peptide, 3
Muscle
  extraocular, 238–253
  frog, 147
  inferior oblique, 239
  thymoma-striated, 63
Muscle biopsies, 451
Muscle contraction, disease severity and, 181
Muscle culture, rat, 156
Muscle fibers, human type 1 and 2, 412
Myasthenia gravis
  childhood, 581
  experimental autoimmune, 264, 285, 292, 295, 299, 539
    thymus in, 50
  hereditary, 165
  history of, 47
  ocular, 238
  passive transfer, 299
  D-penicillamine-induced, 338
  seronegative, 111, 303, 529
    electrophysiological characteristics in, 584
  strategies for treatment of, 515
Myf-4 gene, 103
Myoballs, rat, 147

$^{22}Na^{+}$ flux, carbachol-induced, 534
Nerve terminals, 352
Neurofilaments, expression of, in thymic epithelial tumors, 107
Neuromuscular transmission
  anticholinesterases and, 402
  congenital disorders of, 435
  funnel-web spider toxin and, 405
  safety margin in, 426, 483
Nicotinic acetylcholine receptor α-chain, 74–81
Noise analysis, 431, 502

Ovalbumin$_{257-264}$, 20–22

P3A exon, 220
Paraneoplastic syndrome, 378
Passive antibody transfer, 183
Pathologic mechanisms
  congenital myasthenic syndrome and, 467
  myasthenic syndromes affecting ε-subunit of acetylcholine receptor and, 504
PC12 cells, 374
D-Penicillamine
  chronic exposure to, 319–321
  effects of, on immunogenic epitopes of acetylcholine receptor, 335
Peptide, mouse and *Torpedo*, 2
Peptide-binding site, 16–23
Peptides
  acetylcholine receptor, 295
  synthetic, 127, 168, 231
    of the acetylcholine receptor, 332–334
Peripheral blood leukocyte, human, severe combined immunodeficient mice and, 67
Phosphorylation, differential, 344
Photoaffinity labeling, 145
Physostigmine, neuromuscular transmission and, 140, 148
Plasma exchange, 599
Plasma factors in seronegative myasthenia gravis, 533
Plasmids, bacterial expression, 310
Polymerase chain reaction, 76, 424
Polypeptides, recombinant, 310
Prednisone, 599

Quantal content, 457, 531
Quantal release, reduced, 461
Quantified myasthenia gravis score, 542

Rapamycin, 539
Rapidly degrading acetylcholine receptors, 155
Rat, inbred, disease severity in, 180
Recombinant polypeptides, 224
Relapses, azathioprine treatment and, 591
Repertoires, T-cell, 33
Repetitive nerve stimulation, 567
Restriction fragment length polymorphisms, 458
Reticulocyte tisssues, rabbit, 167

Selection, positive and negative, of T-cell repertoire, 16
Self-tolerance, extrathymic tolerance induction and, 8
Severe combined deficient myasthenic mouse, 303
Severe combined immunodeficient mouse, 66–72
Siblings and parents, 581
Single-fiber electromyography, 567
Slow channel syndrome, 448, 457
Slowly degrading acetylcholine receptors, 155
Small-cell lung cancer, Lambert-Eaton myasthenic syndrome and, 418

Sodium channel distribution, 412
Sodium currents, effects of Lambert-Eaton myasthenic syndrome serum and immunoglobulin G on, 418
Soleus muscle, rat, 155
Somatic hypermutation, 31
Splicing
  alternative, of the α-3 gene, 88
  Alu, 93
Stimulation, electrical, 156
Suppressor cells, 306, 308
Synaptic vesicles, paucity of, 461

T cells
  class I–restricted cytotoxic, 276
  differential recognition by, 280
  human acetylcholine receptor-reactive, 339
  role of, in regulating autoimmune response, 1–4
T-cell activation, 552
T-cell influences on disease, 190
T-cell receptor
  immunization with, 519
  V, D, and J gene elements and, 292
T-cell receptor gene usage, 313
T-helper cell lines, 201
TE671 cells, 534
Tensilon test, 603
Therapeutic intervention, sites for, 516
Therapy
  azathioprine, 592
  intravenous high-dose immunoglobulin G, 563
Thymectomy, 598, 606
  prognostic factors at time of, 556
Thymic microenvironment, 49
Thymic selection, 16
Thymocytes, 68
  role of innervation in maturation of, 84
Thymoma, 607
  seronegative myasthenia gravis and, 530
  T-cell line raised from, 222
Thymoma-associated myasthenia gravis, 56–63
Thymus
  α-3 acetylcholine receptor subunit transcripts in, 83
  acetylcholine receptor antibodies and, 110
  acetylcholine receptor–specific T lymphocytes in, 48–49
  characteristic changes in, in myasthenia gravis, 47–53
  hyperplastic, 223
  regulation of acetylcholine receptor expression by Myf-4 in, 103
  residual, after previous thymectomy, 575
  severe combined immunodeficient mouse, 66–72
  T-cell differentiation in, 6–7
Titer, antibody, and disease threshold, 185
Tolerance
  non-major histocompatibility complex self-antigens and, 8
  T-cell, 33–37
Torpedo acetylcholine receptor, titration of, 175
Transmitter release, 405
Transmitter release face, 371
Transplantation, thymic, 68
Treatment strategies, 603

Vesicular stomatitis virus nucleocapsid protein, 20–23
V_H gene family, 285

X-ray diffraction, small angle, 114

Index of Contributors

Abdul-Karim, F. W., 103–106
Adams, R. N., 298–302
Agius, M., 1–4, 264–273, 274–275
Åhlberg, R., 552–555
Aimo, G., 563–566
Aladjem, M., 126–139
Albuquerque, E. X., 140–155
Andreose, J., 156–164
Antozzi, C., 594–602
Arimori, S., 570–572
Arnason, B. G. W., 303–305
Atassi, M. Z., 329–331
Austin, C., 83–96
Avila, O., 298–302

Baccala, R., 33–46
Baggi, F., 165–167, 219–237, 276–279
Balcer, L., 515–528
Balderas, R. S., 33–46
Barchan, D., 126–139
Barrett-Jolley, R., 529–538
Batocchi, A-P., 219–237, 280–282
Beeson, D. M. W., 165–167, 219–237, 280–282, 422–424, 451–460
Bergamasco, B., 563–566
Bergamini, L., 556–560
Berrih-Aknin, S., 97–99, 100–102, 283–284, 573–574
Berta, E., 594–602
Betty, M., 451–460
Blandino, J. K. W., 394–397, 398–401, 418–421
Bongioanni, P., 303–305
Bos, N., 285–287
Brengman, J. M., 469–486
Bril, V., 487–495
Brydson, M., 165–167
Burges, J., 529–538
Byrne, N., 529–538

Camp, S., 469–486
Carbone, E., 373–381
Carmon, S., 332–334
Casadio, C., 556–560
Catterall, W. A., 342–355
Cavallo, R., 563–566
Chang, S., 292–294
Charron, D., 573–574
Cherksey, B. D., 382–393, 405–407
Christadoss, P., 329–331
Clayman, J., 103–106
Clementi, F., 373–381
Coban, T., 140–155
Coffman, R. L., 25–28
Cohen-Kaminsky, S., 97–99, 100–102, 283–284
Confalonieri, P., 594–602
Conti-Tronconi, B. M., 198–218
Corey, A. L., 264–273
Cornelio, F., 594–602
Currier, P., 292–294

Dalmau, J., 408–411
David, C., 329–331
De Baets, M., 285–287
De Jongh, K., 342–355
Degos, L., 573–574
Delattre, R. M., 97–99
DeSilva, S., 298–302
Devergne, O., 97–99, 100–102
Drachman, D. B., 298–302, 306–309, 325–328, 515–528
Dubel, S. J., 342–355
Duquenoy, J. M., 283–284
Durelli, L., 556–560, 563–566
Dutto, A., 556–560, 563–566
Dwyer, B., 591–593
Dyall, R., 16–24

Egan, D., 408–411
Ehara, M., 581–583
Elechi, C. A., 561–562
Elrington, G., 382–393
Emilie, D., 97–99, 100–102
Engel, A. G., 425–434, 461–468, 469–486, 487–495, 496–508, 509–514

Fairclough, R. H., 1–4, 113–125, 172–174, 175–178, 264–273, 335–338
Faler, J., 292–294
Fenstermaker, R. A., 103–106
Ferrero, B., 556–560, 563–566
Ferri, R., 556–560
Ferrio, M. F., 323–324
Fiacchino, F., 594–602
Fox, S., 575–576
Fuchs, S., 126–139, 332–334
Fumagalli, G., 156–164
Furneaux, H. M., 408–411

Gajdos, P., 573–574
Galanaud, P., 97–99, 100–102
Genkins, G., 603–608

Geuder, K., 56–65
Gilchrist, J. M., 567–569
Godovac-Zimmermann, J., 140–155
Gomez, C. M., 264–273
Graus, Y., 285–287
Greiner, A., 107–109
Griggs, R. C., 496–508
Grimaldi, L. M. E., 303–305
Grob, D., 315–318
Gu, Y., 496–508
Gudipati, E., 1–4

Hall, K., 539–551
Hall, Z. W., 496–508
Harcourt, G., 219–237, 280–282, 288–291
Harper, C. M., 461–468, 469–486, 509–514
Harrison, J., 451–460
Hart, A., 529–538
Hawke, S., 219–237, 280–282, 288–291
Hell, J., 342–355
Hohlfeld, R., 66–73
Holm, G., 552–555
Horiki, T., 570–572
Hors, J., 573–574
Hoshino, T., 382–393
Howard Jr., J. F., 198–218, 588–590
Hulette, C., 83–96
Hutchinson, D. O., 469–486, 496–508

Ichikawa, Y., 570–572
Infante, A. J., 292–294
Inoko, H., 570–572

Jacobson, L., 165–167, 219–237, 295–297
Jacques, J. J., 319–322
Jeremiah, S., 165–167
Johnston, I., 382–393
Josephs, R., 113–125
Juji, T., 581–583

Kachalsky, S., 126–139
Kalbacher, H., 310–312
Kaminski, H. J., 103–106, 435–450
Khalil, I., 573–574
Kim, S. J., 418–421
Kim, Y. I., 394–397, 398–401, 418–421
Kirchner, Th., 56–65, 107–109
Klingel-Schmitt, I., 97–99
Kochva, E., 126–139
Kono, D. H., 33–46
Kornfeld, P., 575–576
Kraig, E., 292–294
Krolick, K. A., 179–197, 292–294
Kuncl, R. W., 298–302

Lang, B., 382–393, 422–424
Lefvert, A. K., 339–341, 552–555
Lehar, M., 298–302
Lepage, V., 573–574
Leung, C., 402–404
Leveque, C., 382–393
Levinson, A. I., 74–82
Leys, K., 382–393
Li, Z., 529–538
Lindstrom, J., 310–312, 313–314, 496–508
Lisak, R. P., 256–263, 323–324, 561–562
Llinás, R., 382–393, 405–407
Loh, E., 74–82
Lomo, T., 156–164
Lost, M. N., 573–574
Lucas, D., 298–302

Maelicke, A., 140–155
Maggi, G., 556–560
Maier, K., 575–576
Malcherek, G., 310–312, 313–314
Manfredi, A. A., 198–218
Manley, G., 408–411
Mantegazza, R., 276–279, 594–602
Marqueze, B., 382–393
Martin-Moutot, N., 382–393
Martino, G., 303–305
Marx, A., 56–65, 66–73, 107–109
Maselli, R. A., 264–273, 402–404
Massey, J. M., 567–569, 588–590
Matell, G., 552–555
Matsuki, K., 581–583
Matsuo, H., 219–237
Mayer, R. F., 591–593
McIntosh, K. R., 298–302, 306–309, 325–328, 515–528
Melms, A., 310–312, 313–314
Merav, A., 575–576
Methfessel, C., 140–155
Mihovilovic, M., 83–96
Mills, K., 451–460
Mittelstaedt, J., 83–96
Moiola, L., 198–218
Mokhtarian, F., 315–318
Molenaar, P., 451–460, 529–538
Moody, A-M., 219–237
Morita, K., 570–572
Moriuchi, J., 570–572
Morris, A., 165–167
Müller, C. A., 313–314
Müller-Hermelink, H. K., 56–65, 107–109
Murphy, L., 496–508
Murray, N., 451–460

Nag, B., 577–580
Nagel, A. S., 461–468, 487–495, 509–514

Nagvekar, N., 219–237
Nakano, S., 469–486, 496–508
Neuman, D., 126–139
Newsom-Davis, J., 165–167, 219–237, 276–279, 280–282, 288–291, 295–297, 382–393, 422–424, 451–460, 529–538, 577–580
Nicolle, M. W., 219–237, 577–580
Nikolić-Žugić, J., 16–24
Nomura, Y., 581–583

O'Malley, J. P., 156–164
O'Shaughnessy, T. J., 398–401
Oda, K., 238–255
Oger, J. J.-F., 110–112
Oh, S. J., 584–587
Oksenberg, J. R., 313–314
Ong, B., 219–237
Oshima, M., 329–331
Ovadia, M., 126–139

Padberg, F., 66–73
Palace, J., 451–460
Pantic, N., 219–237, 280–282
Pecchio, F., 563–566
Peluchetti, D., 594–602
Penn, A. S., xv–xvi, 319–322
Pereira, E. F. R., 140–155
Pestronk, A., 298–302
Phillips, J. T., 539–551
Pirskanen, R., 552–555
Poccardi, G., 556–560
Porter, V., 356–367
Posner, J. B., 408–411
Povey, S., 165–167
Protti, D. A., 405–407
Protti, M. P., 198–218

Quintans, J., 303–305

Ragheb, S., 256–263, 323–324
Reim, J., 325–328, 515–528
Reinhardt-Maelicke, S., 140–155
Richman, D. P., 1–4, 113–125, 172–174, 175–178, 264–273, 274–275, 335–338
Rieber, P., 552–555
Riethmüller, G., 552–555
Roehm, P. C., 306–309
Rollins, J. A., 539–551
Rosenfeld, M. R., 408–411
Roses, A. D., 83–96
Rotman, E., 342–355
Ruff, R. L., 103–106, 412–414, 435–450, 609–611

Salpeter, M. M., 156–164
Sanchez, V. A., 405–407
Sanders, D. B., 567–569, 588–590
Sanyal, B., 274–275
Schalke, B., 107–109
Schoepfer, R., 310–312, 313–314
Schönbeck, S., 66–73
Schrattenholz, A., 140–155
Schröder, B., 140–155
Seagar, M., 382–393
Segawa, M., 581–583
Sghirlanzoni, A., 594–602
Shah, A., 561–562
Sharma, S., 577–580
Shenoy, M., 329–331
Sher, E., 373–381, 408–411
Shillito, P., 295–297, 451–460
Shinohara, Y., 570–572
Shirazian, D., 315–318
Sivak, M., 603–608
Snutch, T. P., 342–355
Sommer, N., 310–312
Souroujon, M. C., 332–334
Sprent, J., 5–15
Stanley, E. F., 368–372
Steinman, L., 313–314
Storb, U., 29–32
Storch, A., 140–155
Sugimori, M., 382–393, 405–407
Swerup, C., 552–555

Takahashi, M., 382–393
Takamori, M., 168–171, 415–417
Tartter, P. I., 603–608
Taylor, P., 469–486
Theofilopoulos, A. N., 33–46
Thompson, P. A., 179–197, 292–294
Tindall, R. S. A., 539–551
Trastek, V. F., 461–468, 487–495
Tsuji, K., 570–572
Twaddle, G. M., 175–178

Uchitel, O. D., 405–407, 487–495
Urso, D., 74–82

Van Breda Vriesman, P., 285–287
Verschuuren, J., 285–287
Viglione, M. P., 418–421
Vincent, A., 165–167, 219–237, 276–279, 288–291, 295–297, 451–460, 529–538, 577–580
Vogel, Z., 126–139

Waisburg, H. A., 509–514
Walls, T. J., 461–468, 469–486, 487–495, 509–514

Wekerle, H., 47–55, 66–73
Wells, L., 539–551
Westenbroek, R., 342–355
Wheatley, L. M., 74–82
Whittlesey, D., 412–414
Wierzbicki, A. S., 422–424
Wiggins, W. W., 298–302
Wilensky, R., 591–593
Willcox, N., 219–237, 280–282, 288–291, 577–580
Wittstein, I., 298–302
Wollmann, R. L., 264–273, 303–305
Wong, E., 408–411
Wray, D., 356–367, 451–460, 529–538

Xu, Q., 1–4, 172–174, 175–178, 335–338
Xu, R., 156–164

Yamamoto, T., 529–538
Yeh, T.-M., 179–197
Yi, Q., 339–341, 552–555
Yuen, M.-H. 198–218

Zborowski, K., 292–294
Zheng, Y., 74–82
Zoda, T. E., 179–197